It’s the holy grail of marijuana research – clinical proof that cannabis really does have medicinal properties

The first company to achieve this breakthrough stands to make a fortune. And this ingenious, emerging company appears to have the inside track. Savvy investors would be well advised to jump in now, because the company is moving forward with the final phase in its research efforts.


There’s a wealth of anecdotal evidence that marijuana has medicinal properties, but there’s no actual clinical proof.

And without that all-important clinical proof, most doctors won’t prescribe cannabis-based medications – and insurance companies surely won’t reimburse patients who use them.

Until now, securing clinical proof has been like looking for the proverbial needle in a haystack.

The plant we know as marijuana or cannabis isn’t a single plant. It’s actually three closely related, but distinctly different, species. And these species have been cross-bred to create more than 700 marijuana strains.

Each of these 700 strains has varying combinations of the 100 or so naturally occurring chemicals (called cannabinoids) that give cannabis its medicinal properties.

Sorting through combinations of these 100 cannabinoids in the 700-plus marijuana strains could take 15 to 20 years and cost about $800 million using standard research methodology.

But this ingenious company has found a shortcut that drastically reduces research time and expense.

Its “fast track” approach is the brainchild of a three-man research team that used it to create Brinavess,® an atrial fibrillation drug (which was licensed to Merck in a deal worth as much as $600 million), as well as drugs for the treatment of asthma, COPD, and cystic fibrosis.

All told, these research superstars have used their fast track methodology to create over $1 billion of shareholder value.

While there are never any guarantees when it comes to medical research, one of the big names in medical marijuana has made a big million-dollar bet that the team will succeed.

Savvy investors would be well advised to jump in now, because the company is moving forward with the final phase in its research efforts.

And when small-cap and micro-cap companies announce results, their share price can go through the roof. For example…

  • Celator Pharmaceuticals went from $1.68 to $9.50 in just one day – a 465% jump!
  • Incyte Corp. went from $2.54 to $131 – a 5,057% gain!
  • Aquinox Pharmaceuticals rocketed from less than $2.00 to around $21.00 in just two weeks – a staggering gain of over +1,100%!

As I detail in my groundbreaking report, investors could see comparable returns if this company is the first to scientifically prove medical marijuana’s effectiveness.

Click HERE to find out the 5 compelling reasons this stock is on the verge of breaking out!

J. William Roberts, B.S., M.B.A., J.D.
for Investors News Service

P.S. The deep-pocketed strategic partner that recently made a big seven-digit investment in the company is regarded as one of the big players in medical marijuana. In the two years since it went public, it has raised over $22 million, acquired properties for marijuana cultivation and processing in three different states, and obtained (or has conditional applications for) up to 11 cannabis licenses in the US and Canada.

If they’re betting big on this emerging company, that’s a very good sign indeed!

J. William Roberts holds a B.S. in business, magna cum laude, from a prestigious university in New England, an M.B.A. from a highly regarded Mid-Atlantic university, and a J.D. from one of the top law schools in the New York metropolitan area, where he served as a law review editor.

Media Contact
Company Name: PublicWire
Contact Person: Dave Donlin
Email: Send Email
Phone: 4074906635
Address:5850 TG Lee Blvd, Suite 300
City: Orlando
State: FL
Country: United States